Amryt Pharma gets revenues boost
drug firm Amryt Pharma, which is focused on finding treatments for rare conditions, has reported revenue of $113.1m (€101m) for the nine months to 30 September, up from $94.5m (€84.6m) in the same period last year.
The performance was helped by the company's acquisition of Aegerion Pharmaceuticals, a former subsidiary of Novelion Therapeutics.
At 31 October the group had cash on hand of $61.2m, according to a trading update from the company.
Dr Joe Wiley, CEO of Amryt Pharma, said: "The first nine months of 2019 have been momentous and transformational for Amryt."
Please log in or register with Independent.ie for free access to this article.
He added that the company was now "well positioned" to execute its strategy of becoming a global leader in the development of treatments for rare diseases.